---
id: idsa-hiv-treatment-2024
title: "DHHS 2024 Guidelines for the Use of Antiretroviral Agents in Adults with HIV"
short_title: "DHHS HIV ART 2024"

organization: Department of Health and Human Services
collaborators:
  - Infectious Diseases Society of America
country: US
url: https://clinicalinfo.hiv.gov/
doi: null
pmid: null
open_access: true

specialty: infectious-disease
guideline_type: clinical-practice
evidence_system: DHHS
conditions:
  - HIV
  - HIV/AIDS
  - antiretroviral therapy
tags:
  - bictegravir
  - dolutegravir
  - TDF
  - TAF
  - viral suppression

publication_date: 2024-03-01
previous_version_date: 2023-09-01
status: current
supersedes: null
superseded_by: null

pdf_path: null
has_pdf: false
last_reviewed: 2025-12-26
---

## Scope
2024 DHHS guideline update on the use of antiretroviral therapy (ART) in adults and adolescents with HIV-1 infection.

## Key Recommendations

### When to Start ART
- **Immediate ART**: Recommend starting ART for all people with HIV (PWH), regardless of CD4 count or viral load, as soon as possible after diagnosis (same-day start if feasible).
- Early ART improves outcomes and reduces transmission.

### Recommended Initial Regimens (INSTI-Based, Preferred)

#### Bictegravir-Based
- **Bictegravir / Tenofovir Alafenamide / Emtricitabine (Biktarvy)**: Single-tablet regimen. Preferred.

#### Dolutegravir-Based
- **Dolutegravir / Abacavir / Lamivudine (Triumeq)**: If HLA-B*5701 negative.
- **Dolutegravir + (TAF or TDF)/FTC or 3TC**: Preferred combination.
- **Dolutegravir / Lamivudine (Dovato)**: Two-drug regimen; option for patients without HBV, VL <500,000.

### Alternative Regimens
- Other INSTIs (raltegravir, elvitegravir/c) or PI-based regimens (darunavir/r or darunavir/c + 2 NRTIs) may be used based on individual circumstances.

### Monitoring
- **Viral Load**: Check 2-4 weeks after starting, then every 3-6 months until suppressed, then every 6 months.
- **CD4 Count**: At baseline and periodically; can be less frequent if consistently >500.
- **Resistance Testing**: Before starting ART (if available) and at virologic failure.

### Goals
- Achieve and maintain viral suppression (<50 copies/mL).
- U=U: Undetectable = Untransmittable.

### Special Populations
- **Pregnancy**: ART for all pregnant PWH. Preferred regimens include dolutegravir-based (safe throughout pregnancy).
- **HBV Coinfection**: Use TDF or TAF + FTC or 3TC (dual activity).
- **Drug Interactions**: Review carefully, especially with INSTIs and divalent cations, statins, rifampin.

### Pre-Exposure Prophylaxis (PrEP)
- Addressed in separate guidelines.
